Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05740007 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
A Phase 2 study, sponsored by Ironwood Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT05740007: Clinical Trial Phase 2 study, sponsored by Ironwood Pharmaceuticals.
NCT05740007 is a Phase 2 study that was terminated before completion, run by Ironwood Pharmaceuticals. The registered enrollment target is 98 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05740007, a Phase 2 study, was terminated before completion, sponsored by Ironwood Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort). Subjects will be assigned to receive either the study drug or placebo by chance.
Primary Outcome
Subject assessment of bladder pain at its worst will be reported via a daily electronic Diary (eDiary)
Interventions
- DRUG Placebo
- DRUG IW-3300 rectal foam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2025-02-06 |
| Phase | Phase 2 |
Why NCT05740007 stopped before completion
NCT05740007 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (26% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05740007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05740007 about?
NCT05740007 is a clinical study titled "A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome". The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). The main question the study aims to answer is whether IW-3300 helps bladder pain and other symptoms (for example, bladder burning, pressure and discomfort)....
What is the current status of trial NCT05740007?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2023-03-28. Estimated completion is 2025-02-06.
What interventions are being tested in trial NCT05740007?
The interventions under investigation include: Placebo (DRUG), IW-3300 rectal foam (DRUG).
Who is sponsoring clinical trial NCT05740007?
This trial is sponsored by Ironwood Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05740007's enrollment target sits among peer trials
98 743rd of 2000 higher than 1,255 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI